

# Middle East Respiratory Syndrome (MERS) R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/M1575EF60AB6EN.html>

Date: October 2020

Pages: 104

Price: US\$ 2,199.00 (Single User License)

ID: M1575EF60AB6EN

## Abstracts

### Middle East Respiratory Syndrome (MERS) Pipeline Overview

The Q4 Middle East Respiratory Syndrome (MERS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Middle East Respiratory Syndrome (MERS), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

### Middle East Respiratory Syndrome (MERS) Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Middle East Respiratory Syndrome (MERS) disease overview, Middle East Respiratory Syndrome (MERS) types, Middle East Respiratory Syndrome (MERS) symptoms, causes, and FDA/EMA approved treatment options.

### Middle East Respiratory Syndrome (MERS) Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Middle East Respiratory Syndrome (MERS) indication. The report presents near-term and long-term pipeline development trends and potential insights.

### Middle East Respiratory Syndrome (MERS) Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 31 companies. Business profiles and contact details of the companies actively perusing Middle East Respiratory Syndrome (MERS) pipeline are assessed.

## Middle East Respiratory Syndrome (MERS) R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Middle East Respiratory Syndrome (MERS) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

## Small Middle East Respiratory Syndrome (MERS) companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Middle East Respiratory Syndrome (MERS) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

## Middle East Respiratory Syndrome (MERS) Pipeline Market News and Developments during 2020

The Middle East Respiratory Syndrome (MERS) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

## Middle East Respiratory Syndrome (MERS) Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

## New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

## Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

## Scope and Coverage

### Middle East Respiratory Syndrome (MERS) pipeline development activities

across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

31 companies are included including Alkido Pharma Inc, AIM ImmunoTech Inc, Anglo Biopharma Ltd, Atriva Therapeutics GmbH, Autoimmune Technologies LLC, Celltrion Inc, Chongqing Zhifei Biological Products Co Ltd, Cocystal Pharma Inc, Future Medicine Co Ltd, Gilead Sciences Inc, Global BioLife Inc Ltd, Greffex Inc, Humabs BioMed SA, Inovio Pharmaceuticals Inc, LegoChem Biosciences Inc, NanoViricides Inc, Novavax Inc, Orgenesis Inc, Ostrich Pharma USA Inc, OyaGen Inc, Phelix Therapeutics LLC, Pulmotect Inc, Regeneron Pharmaceuticals Inc, Ridgeback Biotherapeutics LP, Romark Laboratories LC, SAB Biotherapeutics Inc, Signia Therapeutics, Themis Bioscience GmbH, Theravectys SA, Vaccitech Ltd, Vir Biotechnology Inc,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Middle East Respiratory Syndrome (MERS) pipeline market

## Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

## Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

## Contents

### **1. TABLE OF CONTENTS**

- 1.1 List of Tables
- 1.2 List of Figures

### **2. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE TRENDS AND INSIGHTS**

- 2.1 Dominant Phase type of Middle East Respiratory Syndrome (MERS) Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Middle East Respiratory Syndrome (MERS) Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Middle East Respiratory Syndrome (MERS) pipeline
- 2.5 Active Companies Developing Middle East Respiratory Syndrome (MERS) pipeline

### **3. MIDDLE EAST RESPIRATORY SYNDROME (MERS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS**

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

### **4. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS**

- 4.1 Alkido Pharma Inc
- AIM ImmunoTech Inc
- Anglo Biopharma Ltd
- Atriva Therapeutics GmbH
- Autoimmune Technologies LLC
- Celltrion Inc
- Chongqing Zhifei Biological Products Co Ltd
- Cocrystal Pharma Inc
- Future Medicine Co Ltd

Gilead Sciences Inc  
Global BioLife Inc Ltd  
Greffex Inc  
Humabs BioMed SA  
Inovio Pharmaceuticals Inc  
LegoChem Biosciences Inc  
NanoViricides Inc  
Novavax Inc  
Orgenesis Inc  
Ostrich Pharma USA Inc  
OyaGen Inc  
Phelix Therapeutics LLC  
Pulmotect Inc  
Regeneron Pharmaceuticals Inc  
Ridgeback Biotherapeutics LP  
Romark Laboratories LC  
SAB Biotherapeutics Inc  
Signia Therapeutics  
Themis Bioscience GmbH  
Theravectys SA  
Vaccitech Ltd  
Vir Biotechnology Inc

## **5. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE DRUG PROFILES**

### 5.1 Current Status of Drug and Vaccine Candidates

#### 5.2 Drug Snapshot

##### 5.2.1 Drug

##### 5.2.2 Mechanism of Action

##### 5.2.3 Phase

##### 5.2.4 Co-Developer

##### 5.2.5 Originator

##### 5.2.6 Synonym

##### 5.2.7 Route of Administration

##### 5.2.8 Type of Molecule

##### 5.2.9 Orphan Drug Status

##### 5.2.10 New Molecular Entity

##### 5.2.11 Area

### 5.3 Drug Details

- 5.4 Mechanism of Action
- 5.5 Licensing/Collaboration Agreements
- 5.6 Clinical Trial Details

## **6. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020**

### **7. APPENDIX**

- 7.1 About the Publisher
- 7.2 Sources and Research Methodology

## I would like to order

Product name: Middle East Respiratory Syndrome (MERS) R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/M1575EF60AB6EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1575EF60AB6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970